Eiger BioPharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EIGRQ research report →
About the company
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical firm dedicated to discovering and advancing treatments for critical health issues, particularly hepatitis delta virus (HDV), among other severe diseases. The company's marketed product, Zokinvy, is prescribed for patients suffering from Hutchinson-Gilford progeria syndrome and Processing-Deficient Progeroid Laminopathies.
- CEO
- David Apelian
- IPO
- 2014
- Employees
- 25
- HQ
- Palo Alto, CA, US
Price Chart
- Market Cap
- $12.59M
- P/E
- -0.17
- P/S
- 0.80
- P/B
- -0.87
- EV/EBITDA
- -0.41
- Div Yield
- 0.00%
- Gross Margin
- 95.09%
- Op Margin
- -455.12%
- Net Margin
- -475.26%
- ROE
- -367.00%
- ROIC
- -268.20%
- Revenue
- $15.77M · 16.98%
- Net Income
- $-74,963,000 · 22.54%
- EPS
- $-50.78 · 27.19%
- Op Income
- $-71,786,000
- FCF YoY
- 10.28%
- 52W High
- $16.00
- 52W Low
- $1.10
- 50D MA
- $11.27
- 200D MA
- $6.94
- Beta
- 2.78
- Avg Volume
- 13.61K
Get TickerSpark's AI analysis on EIGRQ
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our EIGRQ coverage
Recent articles, reports, and earnings notes.
No research on EIGRQ yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EIGRQ report →Similar companies
Peers in the same neighborhood.